Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Uncovering practice gaps in the management of mantle cell and diffuse large B-cell lymphomas amidst advances with Bruton's tyrosine kinase inhibitors

Tisheeka Graham, Tariqa Ackbarali, Katie Kowalski et al. Nov 03, 2025 pp. 8106-8106 10.1182/blood-2025-8106

Abstract BACKGROUND: Mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) are two of the most diagnosed subtypes of B-cell n...

The predictive value of the interleukin 2 receptor (IL2)/ferritin ratio in the diagnosis of lymphoma associated hemophagocytic lymphohistiocytosis (LAHS): A United States, multi center experience

Dariusz Uczkowski, Linzi Hobbs-Parker, Stephanie Yohay et al. Nov 03, 2025 pp. 4769-4769 10.1182/blood-2025-4769

Abstract Introduction Hemophagocytic lymphohistiocytosis (HLH) is an inflammatory syndrome that can occur de novo or due...

Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum

David E Mery, Samer Al Hadidi, Clyde Bailey et al. Nov 03, 2025 pp. 2172-2172 10.1182/blood-2025-2172

Abstract Gene Expression–Based Prediction of 1q, 1p, 13q, and 17p Chromosome Ploidy in Serial Newly Diagnosed and Relapsed Myeloma and Acros...

Transfusion burden among older US patients with relapsed FLT3-mutated Acute Myeloid Leukemia treated with gilteritinib: A Medicare claims-based cohort study

Thomas LeBlanc, Alana Block, Christopher Young et al. Nov 03, 2025 pp. 1664-1664 10.1182/blood-2025-1664

Abstract Background : Older patients with relapsed acute myeloid leukemia (AML) often require transfusion support due to persistent cytopeni...

A phase 2 clinical study on intensifying idarubicin dosage for inducing remission in acute myeloid leukemia patients aged 65 and younger

Mark Lee, Tae-Eun Kim, Sung-Yong Kim et al. Nov 03, 2025 pp. 5218-5218 10.1182/blood-2025-5218

Abstract Introduction: Until now, the standard induction therapy for acute myeloid leukemia (AML) has been a continuous infusion of cytarabi...

The surpass trial: a phase 2/3 registrational trial of ELA026 in subjects with treatment-Naïve secondary hemophagocytic lymphohistiocytosis

Swami Iyer, Abhishek Maiti, Prakash Satwani et al. Nov 03, 2025 pp. 1223-1223 10.1182/blood-2025-1223

Abstract Background/Significance: Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory condition wher...

Prognostic value of mayo 2012 vs. european‑modified mayo 2004 staging in AL amyloidosis patients with discordant stage classifications

Miran Han, Sang Eun Yoon, Seokjin Kim et al. Nov 03, 2025 pp. 5738-5738 10.1182/blood-2025-5738

Abstract Background: Systemic AL amyloidosis is a clonal plasma cell disorder characterized by the deposition of misfolded immunoglobulin li...

Reassessing voxelotor safety and efficacy: Real-world outcomes from the ASH research collaborative data hub

Omar Niss, Matthew Fenchel, Charles Abrams et al. Nov 03, 2025 pp. 6226-6226 10.1182/blood-2025-6226

Abstract Voxelotor binds the α-globin subunit of HbS, stabilizing it in the oxygenated state, which may reduce polymerization. Voxelotor was...

Real-world data on cardiovascular disease incidence in adults with acquired immune aplastic anemia.

Manasa Kotamraju, Mayowa Oturoko, Jimmy Lee et al. Nov 03, 2025 pp. 4984-4984 10.1182/blood-2025-4984

Abstract Acquired aplastic anemia (AA) is an immune-mediated bone marrow failure with a high propensity for clonal hematopoiesis (CH), where...

Thrombotic thrombocytopenic purpura with features of evans syndrome in a case of lupus vasculitis

Manas Pustake, Ritwik Dey, Suyog Patel et al. Nov 03, 2025 pp. 6652-6652 10.1182/blood-2025-6652

Abstract Introduction: Thrombotic thrombocytopenic purpura (TTP), distinguished by severe ADAMTS13 deficiency, is an emergency requiring imm...

Overall survival after post-transplant cyclophosphamide (PTCy) peripheral blood hematopoietic cell transplantation (HCT) differs by race, ethnicity, and donor

Megan Herr, Nisha Nair, Shernan Holtan et al. Nov 03, 2025 pp. 963-963 10.1182/blood-2025-963

Abstract Introduction Hispanic and non-Hispanic Black (NHB) patients have worse HCT survival compared to non-Hispanic White (NHW) patients a...

Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights

Rosa Coll, Nuria Brey, Antonella Luciana Sturla et al. Nov 03, 2025 pp. 6896-6896 10.1182/blood-2025-6896

Abstract Background: Secondary acute myeloid leukemia (sAML) continues to be associated with poor prognosis. Identification of subgroups wit...

Delayed pulmonary embolism following oocyte retrieval in invitro fertilization: A neglected risk factor for thromboembolic events?

Chinemerem Emeasoba, Chiugo Okoye, Oluwafemifola Oyedeji et al. Nov 03, 2025 pp. 6672-6672 10.1182/blood-2025-6672

Abstract Introduction: Pulmonary embolism (PE) is a rare complication that is often underdiagnosed following assisted reproductive technolog...

Association between increased Patients' out-of-pocket costs for apixaban and oral anticoagulant discontinuation in high-risk patients with atrial fibrillation - a retrospective Medicare claims study

Dominick Latremouille-Viau, Aolin Wang, Dong Cheng et al. Nov 03, 2025 pp. 954-954 10.1182/blood-2025-954

Abstract Introduction: Atrial fibrillation (AF) affects millions of adults in the United States and is a major risk fact...

Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1–3 prior lines of therapy using a matching-adjusted indirect comparison

Christopher Strouse, Surbhi Sidana, Rafael Fonseca et al. Nov 03, 2025 pp. 4046-4046 10.1182/blood-2025-4046

Abstract Introduction: The CARTITUDE-4 (NCT04181827) trial compared cilta-cel, a chimeric antigen receptor (CAR)-T cell treatment (tx) target...

Impacts of IPSS-m and conditioning intensity in allogeneic hematopoietic cell transplant for patients with myelodysplasia neoplasms

Zilu Zhang, Xiaoqian Xu, Qi Wen et al. Nov 03, 2025 pp. 1062-1062 10.1182/blood-2025-1062

Abstract Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for patients with myelodyspla...

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Ayalew Tefferi, Yassin Bashir, Ahmed Abdelrheem et al. Nov 03, 2025 pp. 3798-3798 10.1182/blood-2025-3798

Abstract Background A previous multicenter study of patients with TP53-mutated myeloproliferative neoplasms showed a significantly shorter su...

Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study

Alexander Röth, Marc Michel, Wilma Barcellini et al. Nov 03, 2025 pp. 6242-6242 10.1182/blood-2025-6242

Abstract Background: Cold agglutinin disease (CAD) and cold agglutinin syndrome (CAS) are cold antibody driven autoimmune hemolytic anemias,...

Intein-based modular assembly of multi-receptor CAR T cells

Bintao Wang, Brandon Ng, Pablo Gonzalez-Garcia et al. Nov 03, 2025 pp. 4125-4125 10.1182/blood-2025-4125

Abstract Background: Chimeric antigen receptor (CAR) T cells demonstrate strong antitumor activity. However, therapeutic success is often li...

Haploidentical donor regulatory T cells and memory T cells are safe and effective in children with refractory graft-versus-host disease with concurrent  viral infections

VictoryIa Vedmedskaia, Dmitriy Pershin, Larisa Shelikhova et al. Nov 03, 2025 pp. 6013-6013 10.1182/blood-2025-6013

Abstract Background: Graft-versus-host disease (GVHD) refractory to immunosuppressive therapy (IST) remains a major complication following a...

Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

Liu Ge, Yile Zhou, Yinjun Lou et al. Nov 03, 2025 pp. 1562-1562 10.1182/blood-2025-1562

Abstract Introduction Blinatumomab, a bispecific antibody targeting CD3/CD19, can significantly improve the complete remission (CR) rate, me...

A retrospective analysis of the safety and effectiveness of recombinant von willebrand factor in children with von willebrand disease undergoing surgery

Tammuella Chrisentery-Singleton, Robert Sidonio, Jr., Angela Weyand et al. Nov 03, 2025 pp. 1301-1301 10.1182/blood-2025-1301

Abstract Background: Von Willebrand disease (VWD) is a bleeding disorder caused by deficient or defective von Willebrand factor (VWF) that c...

The first program for local CD19-CAR-T production and treatment of lymphoma in the UAE update median 1 year follow up and CART cell persistence

Mohamed Abu Haleeqa, Inas El-Najjar, Yandy Marx Castillo Aleman et al. Nov 03, 2025 pp. 3705-3705 10.1182/blood-2025-3705

Abstract Introduction: CD19 CART cell therapy has emerged as an effective treatment option for many patient with Relapsed/Refractory None Hod...

Dioscin suppresses the progression of diffuse large B-cell lymphoma by modulating acaca-dependent histone H3K27 acetylation and inducing mitophagy

Qianqian Guo, Xiaoli Zhou, Xiangxiang Zhou et al. Nov 03, 2025 pp. 1523-1523 10.1182/blood-2025-1523

Abstract Dioscin is a natural steroidal saponin from traditional Chinese medicine with known antitumor properties and clinical applications...

Clinician-assessed eastern cooperative oncology group performance status vs. patient-reported health-related quality of life: Insights from malignant lymphoma

Wei Qin, Zhaoxin Qian, Wendong Chen et al. Nov 03, 2025 pp. 4509-4509 10.1182/blood-2025-4509

Abstract Background: The patient-reported health-related quality-of-life (HRQoL) is an important indicator for measuring the clinical outcom...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page